You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR PEMETREXED DISODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for pemetrexed disodium

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed Lily Research Laboratories Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed National Cancer Institute (NCI) Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
NCT00003706 ↗ LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function Completed The University of Texas Health Science Center at San Antonio Phase 1 1998-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function. PURPOSE: Phase I trial to study the effectiveness of LY231514 in treating patients who have locally advanced or metastatic solid tumors and varying degrees of kidney function.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for pemetrexed disodium

Condition Name

291490051015202530Lung CancerStage IV Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung Cancer[disabled in preview]
Condition Name for pemetrexed disodium
Intervention Trials
Lung Cancer 29
Stage IV Non-Small Cell Lung Cancer 14
Stage IIIA Non-Small Cell Lung Cancer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

6957120010203040506070Lung NeoplasmsCarcinoma, Non-Small-Cell LungMesothelioma[disabled in preview]
Condition MeSH for pemetrexed disodium
Intervention Trials
Lung Neoplasms 69
Carcinoma, Non-Small-Cell Lung 57
Mesothelioma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pemetrexed disodium

Trials by Country

+
Trials by Country for pemetrexed disodium
Location Trials
United States 975
China 32
Canada 15
United Kingdom 9
Spain 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for pemetrexed disodium
Location Trials
Ohio 40
Illinois 37
California 35
Michigan 35
North Carolina 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pemetrexed disodium

Clinical Trial Phase

20.3%78.5%00102030405060Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for pemetrexed disodium
Clinical Trial Phase Trials
Phase 4 1
Phase 3 16
Phase 2 62
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

64.8%21.6%13.6%00102030405060CompletedTerminatedRecruiting[disabled in preview]
Clinical Trial Status for pemetrexed disodium
Clinical Trial Phase Trials
Completed 57
Terminated 19
Recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pemetrexed disodium

Sponsor Name

trials01020304050607080National Cancer Institute (NCI)Alliance for Clinical Trials in OncologyEli Lilly and Company[disabled in preview]
Sponsor Name for pemetrexed disodium
Sponsor Trials
National Cancer Institute (NCI) 80
Alliance for Clinical Trials in Oncology 12
Eli Lilly and Company 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

52.4%38.1%9.5%0-100102030405060708090100110120OtherNIHIndustry[disabled in preview]
Sponsor Type for pemetrexed disodium
Sponsor Trials
Other 110
NIH 80
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Pemetrexed Disodium: Clinical Trials, Market Analysis, and Projections

Introduction to Pemetrexed Disodium

Pemetrexed disodium is a chemotherapy drug used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). It is administered intravenously and often used in combination with other drugs such as cisplatin and pembrolizumab.

Clinical Trials and Efficacy

Study JMDB: First-Line Treatment for NSCLC

In the multi-center, randomized Study JMDB, pemetrexed was evaluated in combination with cisplatin versus gemcitabine with cisplatin in chemotherapy-naive patients with Stage IIIb/IV NSCLC. The study showed that pemetrexed with cisplatin improved overall survival compared to gemcitabine with cisplatin[1].

Study JMEN: Maintenance Therapy for NSCLC

The JMEN study assessed pemetrexed as maintenance therapy following first-line platinum-based chemotherapy in patients with Stage IIIb/IV NSCLC. Patients receiving pemetrexed showed improved overall survival compared to those receiving a placebo[1].

Study PARAMOUNT: Extended Maintenance Therapy

The PARAMOUNT study further evaluated pemetrexed as extended maintenance therapy in patients with non-squamous NSCLC who had completed four cycles of pemetrexed plus cisplatin. The results indicated that continued pemetrexed treatment improved overall survival[1].

Study JMEI: Comparison with Docetaxel

In Study JMEI, pemetrexed was compared to docetaxel in patients with recurrent or progressive NSCLC after one prior chemotherapy regimen. The study demonstrated that pemetrexed was non-inferior to docetaxel in terms of overall survival and showed a trend towards superior survival[1].

Study JMCH: Treatment for Malignant Pleural Mesothelioma

The JMCH study evaluated pemetrexed in combination with cisplatin versus cisplatin alone in chemotherapy-naive patients with malignant pleural mesothelioma. The combination of pemetrexed and cisplatin resulted in a 2.8-month gain in median survival compared to cisplatin alone[1][3].

Market Analysis

Global Market Size and Growth

The global pemetrexed market was valued at USD 2.27 billion in 2022 and is projected to reach USD 2.61 billion by 2031, growing at a CAGR of 1.6% during the forecast period (2023-2031)[2].

Regional Market Dynamics

North America is the largest shareholder in the global pemetrexed market, driven by the high prevalence of lung cancer and increasing demand for chemotherapy drugs. The Asia-Pacific region is expected to be the fastest-growing market due to rising cancer incidence and improving healthcare infrastructure[2].

Market Drivers

The market is driven by several factors, including:

  • Increasing Prevalence of Lung Cancer: Lung cancer is one of the most common types of cancer, with approximately 235,760 new cases estimated in the U.S. in 2021[2].
  • Rising Demand for Chemotherapy: The surge in chemotherapy drug intake due to the growing number of cancer cases is a significant driver[2].
  • Advancements in Treatment: The introduction of new advanced therapies and products, as well as government initiatives, are expected to provide opportunities for market growth[2].

Market Restraints

Despite the growth, the market faces some restraints:

  • Side Effects: Pemetrexed can cause serious side effects such as skin rashes, lung problems, and other adverse reactions, which may deter some patients from using the drug[2].
  • Competition from Alternative Treatments: The presence of other chemotherapy drugs and emerging treatments could pose a challenge to the market growth of pemetrexed[2].

Market Projections

Forecast Period

The pemetrexed market is expected to experience sustained growth from 2023 to 2031. Key factors influencing this growth include:

  • Increasing Incidence of Mesothelioma: The rare but deadly cancer, often caused by asbestos exposure, contributes to the demand for pemetrexed[2].
  • Expansion of Indications: Efforts by key market players to expand the indications of pemetrexed are likely to increase sales and revenues[2].

New Developments and Innovations

Recent developments, such as the launch of ready-to-dilute generic pemetrexed by Sandoz in 2021, aim to improve patient safety and reduce contamination risks. These innovations are expected to enhance market dynamics and patient compliance[2].

Key Takeaways

  • Clinical Efficacy: Pemetrexed has shown significant efficacy in various clinical trials for NSCLC and malignant pleural mesothelioma.
  • Market Growth: The global pemetrexed market is projected to grow at a CAGR of 1.6% from 2023 to 2031.
  • Regional Dynamics: North America is the largest market, while the Asia-Pacific region is expected to be the fastest-growing.
  • Drivers and Restraints: The market is driven by the increasing prevalence of lung cancer and advancements in treatment, but faces restraints due to side effects and competition.

FAQs

What is pemetrexed disodium used for?

Pemetrexed disodium is used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC), often in combination with other drugs like cisplatin and pembrolizumab[4].

What are the key clinical trials that have evaluated pemetrexed disodium?

Key trials include Study JMDB, Study JMEN, Study PARAMOUNT, Study JMEI, and Study JMCH, which have evaluated pemetrexed in various settings for NSCLC and malignant pleural mesothelioma[1].

What is the current market size and growth projection for pemetrexed disodium?

The global pemetrexed market was valued at USD 2.27 billion in 2022 and is projected to reach USD 2.61 billion by 2031, growing at a CAGR of 1.6% during the forecast period[2].

What are the main drivers of the pemetrexed market?

The market is driven by the increasing prevalence of lung cancer, rising demand for chemotherapy, and advancements in treatment options[2].

What are the potential restraints to the pemetrexed market?

The market faces restraints due to the side effects associated with pemetrexed and competition from other chemotherapy drugs and emerging treatments[2].

Which regions are expected to see significant growth in the pemetrexed market?

North America is the largest market, and the Asia-Pacific region is expected to be the fastest-growing due to rising cancer incidence and improving healthcare infrastructure[2].

Sources

  1. Pfizer Medical Information: Pemetrexed Disodium (Solution) Vial Clinical Studies.
  2. Straits Research: Pemetrexed Market Size, Share & Trends Analysis Report.
  3. NIHR: Pemetrexed disodium for the treatment of malignant pleural mesothelioma.
  4. National Cancer Institute: Pemetrexed Disodium.
  5. Market Research Intellect: Global Pemetrexed Disodium for Injection Market Size, Trends and Forecast.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.